Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Regional Coverage

Asia Pacific

Set Alert for Asia Pacific

Latest From Asia Pacific

Interview: Eisai India Unit’s Pivotal Role As Japan Genericizes

Eisai India chief Dr. Sanjit Singh Lamba outlines the competitive edge that the Japanese group’s Indian site offers under the deal with Nichi-Iko; the site has also never “depended” on active pharmaceutical ingredients from China. In a wide-ranging interview with Scrip, Lamba also discusses recent quality compliance initiatives in India.

India Commercial

GC-Yuhan Orphan Alliance Signals Changing Korean Views On Open Innovation

In what appears to be the first open innovation-based partnership between leading South Korean pharma firms, GC Pharma and Yuhan have agreed to conduct joint early research on orphan drugs, capitalizing on each others' strengths. The move may herald a shift in domestic companies' views on such collaboration and a possible increase in similar tie-ups, amid their ongoing efforts to pursue innovation.

South Korea Research & Development

Deal Watch, Focus On Asia: Cipla Licenses India Rights To Lilly’s Basalgar

Cipla expands on its in-licensing strategy in India with Lilly’s insulin glargine product, while Aptose signs second agreement with CrystalGenomics to add Chinese rights for leukemia candidate CG-806, and Yakult gains Japanese rights to Verastem's duvelisib.

Asia Pacific Deals

Samsung, Celltrion Aim For Biosimilar Confidence, Convenience With New Studies

South Korean biosimilars companies Samsung Bioepis and Celltrion presented new study results, designed to increase overall switching rates away from the branded originator therapies and address prescriber concerns as well as improve administration convenience, at the European League Against Rheumatology (EULAR 2018) held June 13-16 in Amsterdam, Netherlands.

Biosimilars Research & Development

Opdivo Approval Opens China I-O Doors But Pricing Key

China approves first immuno-oncology drug in the form of BMS’s Opdivo for lung cancer, opening up a new potentially huge market for the class, but much will depend on pricing and reimbursement policies.

China Cancer

Eisai Refocuses AiM As It Builds US Immuno-Dementia Research

Amid multiple industry drug failures in the sector, Eisai is opening a new US research facility to discover innovative therapies for dementia based on a long-standing immunology hypothesis.

Neurology Research and Development Strategies
See All

Europe

Set Alert for Europe

Latest From Europe

IGEM Therapeutics: Pursuing Novel IgE Antibodies For Solid Tumors

Emerging Company Profile: IGEM Therapeutics has been spun out of King's College London to evaluate the use of IgE-based monoclonal antibodies for the treatment of cancer, including difficult-to-reach solid tumors.

StartUps and SMEs Cancer

Calliditas IPO To Support Phase III Berger's Disease Study

Calliditas is aiming to raise new funding in an IPO and listing on Nasdaq Sweden to support late-stage clinical development and commercialization of its Berger's disease candidate, and studies in additional indications.

 

Financing Renal

SOTIO Aims To Become A Diverse Oncology Company

Cancer vaccine development is not the only R&D avenue being pursued by the Czech Republic-based biotech, SOTIO, which is aiming to become a fully-integrated biopharma company.

Clinical Trials Cancer

Takeda Secures TiGenix But Investor Shire Concerns Bubble Up

Takeda has closed its $630m acquisition of European regenerative medicine company TiGenix following a successful bid process, but is facing new pressure from a group of shareholders in Japan concerned about its planned purchase of Shire – valued at around 100 times that amount.

M & A Japan

Menopausal Symptoms Cooled By KaNDy's Dual Neurokinin Antagonist

Faster relief of debilitating menopausal symptoms in early-stage clinical trial results suggest a potential new class of products being evaluated by UK biotech KaNDy Therapeutics may be useful against the condition.

Clinical Trials Metabolic Disorders

Pharma's UK Pay Gap: An Infographic

For any company its gender pay gap reveals its organizational building blocks; who is predominantly at the top of the pile, and who forms the foundations upon which those at loftier positions sit. Overall, the 19 pharma companies operating in the UK for which we had data fare relatively well, with the lower and middle echelons of the industry overwhelmingly in female favor. However, when it comes to the top-paying positions it all tumbles down, with 74% of the structure taken up by men. This infographic gives a snapshot of how pharma in the UK is organized.

United Kingdom Companies
See All

United States

Set Alert for United States

Latest From United States

Dr. Reddy's Launches First Generic Suboxone Film; Indivior May Seek Injunction

Launch comes immediately after FDA approval of Dr. Reddy's and Mylan ANDAs while Indivior appeals district court ruling of non-infringement; Mylan settlement may delay its entry.

Generic Drugs Approvals

Eisai Refocuses AiM As It Builds US Immuno-Dementia Research

Amid multiple industry drug failures in the sector, Eisai is opening a new US research facility to discover innovative therapies for dementia based on a long-standing immunology hypothesis.

Neurology Research and Development Strategies

Big Pharma Voluntary List Price Reductions Doubtful, Sen. Warren Says

Companies responding to inquiries from Sens. Elizabeth Warren, D-Mass., and Tina Smith, D-Minn., did not indicate they are planning to reduce list prices, despite promises by President Trump, Warren told a June 12 hearing. 
Pricing Debate Pharmacy Benefit Management

Mission Fulphila - Mylan-Biocon Biosimilar Neulasta Takes The Stage In US

The first FDA-approved Neulasta biosimilar is here, opening up material earnings opportunities for partners Mylan and Biocon and affirming the duo's ability to deliver on their complex but high-value pipeline.

Biosimilars Strategy

Turkish Health VC Fund Will Invest In US

Turkey will found a venture capital fund to acquire promising pharmaceutical start-ups and to support Turkish researchers in the US. The initiative comes from the industry, with support from the Turkish government. It is expected to gather pace after the elections on June 24.

Turkey United States

J&J Muscles Into CAR-T Field: Initiates Myeloma Studies

An autologous CAR-T therapy in development by Janssen and Legend Biotech is expected to kick-off US clinical studies in the second half of 2018, adding to the race to apply the new technology to multiple myeloma.

Clinical Trials ImmunoOncology
See All
UsernamePublicRestriction

Register